Startup Juno raises $120m for 'unprecedented' immunotherapies
This article was originally published in Scrip
Executive Summary
The size of Juno Therapeutics's Series A venture funding round is a bright neon sign illuminating the drug development industry's growing enthusiasm for immunotherapies that can train patients' immune systems to attack cancer cells.
You may also be interested in...
Affini-T Raises $175m For Bicoastal TCR Play Focused On KRAS-Mutated Solid Tumors
With Vida Ventures and Leaps by Bayer leading the round, Affini-T raises $175m to advance its KRAS-targeted T-cell therapies into the clinic and add technological capabilities.
Flagship, ARCH Close VC Funds Totaling $2.56bn
Flagship Pioneering raised $1.1bn to fund life science companies emerging from Flagship Labs. ARCH, another frequent start-up co-founder, raised two funds totaling $1.46bn to back early-stage biotech.
Finance Watch: Former Juno Execs Launch Sana With Allogeneic Cell Therapy Platform
Private Company Edition: Former Juno execs launch allogeneic cell therapy venture Sana, Atlas raises a $250m fund, and the Rakuten Aspyrian, Apollomics and Antengene VC deals exceed the $100m mark.